There is a growing movement of professionals seeking jobs with a purpose. The mission-driven culture of a company is a powerful attraction for those value-driven prospective applicants. Curing HIV is one of the bolder missions to be found in the I-270 technology corridor. With its bold mission to develop a cure for HIV, American Gene Technologies Business Development head Norman Rogers said that it’s an “attractive position for people who want a front seat to history.”
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]
The Amicus facility encompasses 75,000 square feet of the top three floors of a new building located on Market Street in Philadelphia. The space includes office space, as well as state-of-the-art laboratories. It’s expected to provide space for approximately 200 researchers and drug developers focused exclusively on gene therapies.
With a goal of expanding manufacturing capabilities to meet the growing demands of cell and gene therapy production, The Center for Breakthrough Medicines (CBM) promoted Chief Operating Officer Joerg Ahlgrimm to the role of Chief Executive Officer. Ahlgrimm joined CBM last year after serving as Head of Global Operations Pharma Biotech and Nutrition at Lonza. CBM, located within the Discovery Labs campus in suburban Philadelphia, is a quickly growing contract development and manufacturing organization that aims to provide pre-clinical through commercial manufacturing capabilities for client companies. CBM’s offerings include process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.
Luke Thorstenson, director of business development at cell and gene therapy and production technology firm Orgenesis, also says digitized manufacturing is key to production scaleup.
“A significant challenge in the production of pharma and biotech products is the automation and integration of individual manufacturing operations,” he tells GEN. “Transitioning from the current ‘analog’ labor-intensive manufacturing process to machine automated processes like those in our Orgenesis Mobile Processing Units and Labs (OMPULs) requires digitization and will allow for the same activities currently done manually by an operator to efficiently scale. We believe these steps are necessary to make life saving treatments like CAR-T available, accessible and affordable.”
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore
BECOME A PART OF THE NEXT GENERATION OF INNOVATORS. Tuesday, June 29 6 – 8 p.m. Engineering and Math Building, Second Floor Lobby Learn about our programs in science, technology, [….]
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
Life Sciences Talent Pipeline Collaborative
Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.